Chronic inflammation disease biotechnology company Evommune applies for a US IPO aiming to raise $100 million
Biotechnology company Evommune submitted an IPO application to the U.S. Securities and Exchange Commission on Thursday, planning to raise up to $100 million. The company focuses on the treatment of chronic inflammatory diseases, with its core candidate drug EVO756 currently undergoing Phase 2b clinical trials, with results expected to be announced in 2026. Evommune was founded in 2020 and plans to list on the New York Stock Exchange under the ticker symbol EVMN
According to the Zhitong Finance APP, Evommune (EVMN.US), a biotechnology company focused on developing therapies for chronic inflammatory diseases and currently in the Phase 2 research and development stage, submitted an application to the U.S. Securities and Exchange Commission (SEC) on Thursday, planning to raise up to $100 million through an initial public offering (IPO).
It is understood that Evommune's core candidate drug, EVO756, is a potent and highly selective oral small molecule MRGPRX2 antagonist for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD). Another drug in development by the company is EV0301, a long-acting fusion protein composed of an IL-18 binding protein and an anti-serum albumin Fab-related domain, suitable for the treatment of atopic dermatitis (AD) and ulcerative colitis (UC). Currently, Evommune has initiated a Phase 2b clinical trial for EVO756, with results expected to be announced in the second half of 2026; at the same time, it plans to start a Phase 2 clinical trial for moderate to severe ulcerative colitis (UC) patients in 2026.
Founded in 2020 and headquartered in Palo Alto, California, the company achieved revenue of $3 million in the 12 months ending June 30, 2025. The company intends to list on the New York Stock Exchange under the ticker symbol EVMN. Previously, on May 14, 2025, Evommune had submitted an IPO application confidentially. The joint book-running managers for this transaction include Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor Fitzgerald, with the pricing terms of the offering yet to be disclosed
